Toll Like Receptor 8 (CD288 or TLR8) - Drugs in Development, 2021
- $ 3500
- April 2024
- 111 pages
BDB-## is under development for the treatment of solid tumors including bladder cancer, ER+ breast cancer, HER2+ cancer, triple negative breast cancer, colorectal cancer, esophogeal cancer, gastric cancer, head and neck cancer, non-squamous non-small cell lung cancer, squamous non- small cell lung cancer, melanoma, prostate cancer and renal cell cancer. [...] Seven and Eight Biopharmaceuticals (formerly known as Birdie Biopharmaceuticals) is developing BDB-## for the treatment of solid tumors including bladder cancer, ER+ breast cancer, HER2+ cancer, triple negative breast cancer, colorectal cancer, esophogeal cancer, gastric cancer, head and neck cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, melanoma, prostate cancer and renal cell cancer.